Chairman of the Scientific Advisory Board, Chief Science Offer and Director, Gb Sciences/GbS Global Biopharma, Inc.
VP Innovation, Professor of Natural Sciences & Mathematics at ChaminadeÂ
University
Director of the PD and Movement Disorders Program and The Ruvo Family Chair, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV
Assoc. Professor, Univ. of Hawaii-John A Burns School of Medicine, Center for Cardiovascular Research
Dr. Andrea Small-Howard has more than 20 years of scientific research experience; as well as executive experience in the biopharmaceutical industry supervising research and development, manufacturing, and quality control divisions in both the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization.
Â
Dr. Small-Howard has been named an inventor on more than sixty patent applications and taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and numerous international regulatory agencies. Currently, Dr. Andrea Small-Howard leverages her broad biopharmaceutical industry knowledge as the Chief Science Officer and member of the Board of Directors at both GB Sciences, Inc. (OTCQB:GBLX), and their wholly-owned Canadian subsidiary, GBS Global Biopharma, Inc. Dr. Small-Howard brings her passion for advancing research on phytochemical compounds to her current roles.
She envisages bringing more phytomedicines to market through an innovative AI-based drug discovery engine and biopharmaceutical drug development program for disease-specific indications. Dr. Small-Howard has worked on cannabinoids for over 20 years, leading a project group dedicated to the study of cannabinoids in the immune system as an NIH-funded post-doctoral fellow. In this work she published one of the earliest studies of cannabinoid impacts on pro-inflammatory immunocytes.
Â
More recently she has contributed to published studies on consumer protection issues surrounding âmedicinalâ plant chemovars in Nevada, co-authored scholarly reviews on cannabinoids in heart disease and Parkinsonâs Disease (PD), co-authored mechanistic studies on cannabinoid and terpene regulation of ion channels, and co-authored an innovative study demonstrating the utility of nanoparticles as delivery vehicles for plant-derived therapeutic compounds.
Dr. Small-Howard is the architect of a strategic vision at GB Sciences/GBS Global Biopharma to make safe, effective, standardized cannabinoid medicines available to patients where its use can be supported with rigorous evidence. To achieve standardization in their cannabinoid-containing, optimized therapeutic mixtures, the Company is using synthetic cannabinoids produced under current Good Manufacturing Practices (cGMP), which are identical in both structure and function to the homologous plant cannabinoids
Helen Turner is Vice President of Innovation and a Professor in the Division of Natural Sciences and Mathematics at Chaminade University in Honolulu, Hawaii. She is a tenured Professor of Biology at Chaminade, and holds an affiliate Professorship at the University of Hawaii School of Medicine.
Â
Dr. Turner moved to the U.S. in 1998 from her native England. After completing her Ph.D. at the University of London she carried out post-doctoral work at Harvard medical School as a Wellcome Trust International Prize Travelling Fellow. In 2000, she accepted a position as Associate Director of Research and Professor at The Queenâs Center for Biomedical Research in Honolulu. Here, she built a successful and internationally recognized research laboratory, receiving her first NIH RO1 grant at the age of 30. Her research interests focus upon information transmission in the immune system, specifically on the molecular mechanisms that activate the pro-inflammatory mast cells. She has trained numerous graduate students and post-doctoral fellows for successful careers in academia, industry and science policy. She is a sought-after reviewer of Federal and Foundation grants, and she sits on a number of executive boards for research and training initiatives in the sciences.
Â
Since joining Chaminade in 2007, Dr. Turner has fostered transformational growth in the sciences.
As a Federallydesignated Native Hawaiian serving institution, Chaminade is positioned to lead in undergraduate science education, serving students and community in Hawaii and the Pacific. She has led the $14m renovation of instructional and research laboratories, raised $20m in funding for the initiation of a BSN program, and secured Chaminadeâs first major research and programmatic funding from agencies such as NIH, NSF and the Department of Defence. New faculty hires and major instrumentation grants have invigorated the undergraduate experience in sciences, and complete curriculum revision in computational sciences and the biological sciences has been completed. Curriculum and faculty research interests now align around the mechanisms and epidemiology of diseases that disproportionately affect the peoples of the Pacific, allowing the University to envision itself as a center of excellence for training and education in this field.
Â
Dr. Norbert E. Kaminski is a Professor in the Department of Pharmacology and Toxicology and is the Director of the Institute for Integrative Toxicology, at Michigan State University. Dr. Kaminskiâs laboratory has been investigating the molecular mechanisms by which cannabinoids alter immune competence for over 22 years, which began with his laboratoryâs discovery of cannabinoid receptor expression within cells of the immune system.
Â
Dr. Kaminski has over 30 years of experience in conducting hypothesis driven investigative research directed at elucidation of the cellular and molecular mechanisms by which drugs and chemicals alter immune competence. These immunopharmacological and immunotoxicological studies have utilized approaches spanning measurements of immune function in vivo, ex vivo and in vitro employing rodent and human primary leukocytes and cell lines. Dr. Kaminskiâs laboratory has also had a longstanding focus on elucidation of the molecular mechanisms that are responsible for impairment of B cell function by dioxins. He is the author of over 135 journal articles 25 Book Chapters and Reviews and 245 Abstracts.
Â
Dr. Kaminski joined the Michigan State faculty in 1993. He was also affiliated with the Medical College of Virginia in their Department of Pharmacology and Toxicology from 1985-1999. He received his B.A. in Chemistry in 1978 from Loyola University in Chicago, Illinois, and his M.S. in Toxicology in 1981 and Ph.D. in Toxicology and Physiology in 1985 from North Carolina State University in Raleigh, North Carolina
Â
Dr. Kaminski has served on a number of advisory panels including National Academy of Science/IOM Review of the Health Effects in Vietnam Veterans of Exposure to Herbicides, 1992-1994; US EPA Science Advisor Board-Dioxin Reassessment Review, 1995; National Academy of Sciences IOM Study on the Assessment of the Health Implications of Exposure to Dioxins, National Academy of Sciences Study on the Health Effects of Cannabinoids, and is presently on the National Academy of Sciences Committee on Emerging Science on Environmental Health. Dr. Kaminski was a member of the Board of Trustees: International Life Sciences Institute-Health and Environmental Sciences Institute 2003-2012.
Â
Dr. Kaminski has also served on a number of peer review panels including US EPA Science Review Panel for Health Research, 1990-92 and NIH ALTX-4 Study Section as a regular member from 1998-03; as an ad hoc member for NIDA, NIEHS, NIOSH, and Wellcome Trust. Dr. Kaminski served as a member of the National Advisory Environmental Health Sciences Council, Division of Extramural Research and Training for NIEHS. Dr. Kaminski served as Treasurer for the Society of Toxicology from 2005-2007. Dr. Kaminski served as the President for the Society of Toxicology from 2014- 2015.
Dr. Carlos F. Rios-Bedoya is the Corporate Director of Scholarly Inquiry at McLaren Health overseeing research across 13 health care facilities with over 30 residency programs in Michigan.
Â
Dr. RĂos-Bedoya has been a principal investigator and co-investigator in several highly competitive federal (CDC), state (Michigan Department of Community Health), and private (Pfizer, Gilead, and Boehringer-Ingelheim) funded grants in the areas of HCV, drug use epidemiology, clinical trials, mental health, and mobile technology. Dr. Rios-Bedoya has an extensive publication record in peer-reviewed journals on the field of legal and illegal drug use on topics such as HCV/HIV, statistical methods, use of mobile technology, and differences across Hispanic groups.
Â
Dr. Carlos F. RĂos-Bedoya graduated in 1986 from the University of Puerto Rico, RĂo Piedras Campus, with a Bachelor of Science (B.S.) degree majoring in biology. In 1987, he finished a Masters in Public Health (M.P.H.) with a concentration in epidemiology also from the University of Puerto, Medical Sciences Campus, and in 1999 he completed his doctoral training (Sc.D.) in Psychiatric Epidemiology with a minor in biostatistics from The Johns Hopkins Universityâs Bloomberg School of Public Health. He did a three-year post-doctoral training (2004-2007) as a National Institute on Drug Abuse (NIDA) fellow on the quantitative aspects of drug dependence epidemiology from The Johns Hopkins Universityâs Bloomberg School of Public Health. He has been a faculty member of the Ponce School of Medicine (1994-2004), the San Juan Bautista School of Medicine (2012-2014), and the College of Human Medicine at Michigan State University (2007- 2015).
Â
Dr. RĂos-Bedoya has been invited to present his research at national and international meetings. He currently serves as grant reviewer for the Florida Department of Healthâs Multi-Disciplinary, Multi-Institutional and Community-Based (MMC) Grants Program and for the Substance Abuse and Mental Health Services Administration (SAMHA). He is also a reviewer for several of the most prestigious peer-reviewed journals in drug use research (e.g., Nicotine and Tobacco Research, Addiction, Drug and Alcohol Dependence, Psychology of Addictive Behaviors, Addiction Medicine, and American Journal of Preventive Medicine).
Dr. Zoltan Mari graduated first in his medical school class in Hungary before completing a post-doctoral fellowship in SUNY Downstate (Brooklyn, NY) on Parkinson disease (PD) animal models and electrophysiology. He finished his neurology residency training in the same institution, where he also served as Chief Resident and was elected to the prestigious Alpha Omega Alpha Medical Honor Society.
Â
After his clinical fellowships in both movement disorders and clinical neurophysiology at NIH, he joined Johns Hopkins University faculty, where he was later promoted to Associate Professor and served as Director of the PD & Movement Disorder Division and Center, which has grown markedly under his leadership, including many successful hires and establishing a DBS Center and a clinical fellowship program.
Â
After 11 years at Johns Hopkins, Dr. Mari joined the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV in May 2017, where he is the Director of the PD and Movement Disorders Program and serves as The Ruvo Family Chair. Dr. Mari is a renowned expert of PD and movement disorders clinical research and the endowment funds will enable him to study novel remote monitoring technologies, biomarkers, and disease modification.
Â
Dr. Mari has published 70 peer-reviewed papers, authored multiple book chapters, and founded and directed many nationally recognized CME programs. He is a co-founder of Neuraly, Inc. which is developing a revolutionary disease modifying treatment for PD and coauthor on a patent regarding the use of transcranial direct current stimulation in PD.
Dr. Alexander Stokes has an impeccable pedigree from a twenty-five career in research and development. Dr. Stokes has an excellent track record of cutting-edge research that was established at world-class European and U.S. institutions including Genzyme, Britainâs Imperial Cancer Research Fund, and Harvard Medical School. Dr. Stokes has published in leading journals such as Nature, and Dr, Stokes has been competitively funded through NIH for the past decade. His early career mentors were under millennium Nobel Prize winner, Dr. Paul Nurse, and Harvard Professor, Dr. Jean-Pierre Kinet, founder of Synta Pharmaceuticals and AB Sciences S.A. Together with graduate degrees in Bioengineering, International Biotechnology, and a PhD in Molecular Physiology, this training positioned him to integrate academic science with real-world translational therapeutic goals.
Â
In 2000, Dr. Stokes was recruited as one of the founding scientists for a new ion channel-focused research institute in Hawaii (the Queenâs Center for Biomedical Research), and his work helped this institute grow an impressive portfolio of high-profile papers in TRP channel biology, major NIH funding and intellectual property and subsequent licensing. Recruited to the Cardiovascular Center of Excellence at the University of Hawaii in 2007, Dr. Stokes recognized that leveraging the tremendous pharmaceutical potential of TRP channels relied on the development of sophisticated in vivo models for their role in human pathology, and this highly translational pre-clinical work dominated his research agenda for next 7 years. His approaches and findings transformed TRVP1 from a minor target in analgesia to a major player in the billion-dollar cardiovascular market space and offers real hope to millions of patients afflicted by heart failure. This intellectual property is the basis for Makai Biotechnology, LLC.
Â
MobilnĂ pĆĂstup ke Spinbetter je uveden pro zaĆĂzenĂ Android a iOS. Zahrnuje nativnĂ aplikaci a takĂ© mobilnĂ webovou aplikaci, takĆŸe nejde pouze o jednu cestu na telefon Äi tablet.
NativnĂ aplikace je dostupnĂĄ pro oba uvedenĂ© operaÄnĂ systĂ©my. MobilnĂ webovĂĄ aplikace pĆedstavuje alternativu pĆes prohlĂĆŸeÄ; popis mobilnĂch moĆŸnostĂ vĆĄak sĂĄm o sobÄ nepotvrzuje, ĆŸe se funkce v prohlĂĆŸeÄi a aplikaci pĆesnÄ shodujĂ.
RozliĆĄenĂ mezi instalovanou aplikacĂ a webovou aplikacĂ pomĂĄhĂĄ pĆi vĂœbÄru pĆĂstupovĂ© cesty; Spinbetter zde oznaÄuje platformu, pro kterou jsou obÄ mobilnĂ varianty zaznamenĂĄny.
UvedenĂ© funkce se tĂœkajĂ rĆŻznĂœch typĆŻ informacĂ a aktivit, nikoli pouze kasinovĂœch her. PĆi mobilnĂ relaci jsou zaznamenĂĄny tyto moĆŸnosti:
Tyto prvky popisujĂ mobilnĂ prostĆedĂ, v nÄmĆŸ se vedle kasina mohou objevovat i sportovnĂ funkce. Pro desktop je proto nelze automaticky povaĆŸovat za potvrzenĂ stejnĂ©ho rozhranĂ nebo stejnĂ© nabĂdky; jde o konkrĂ©tnĂ zĂĄznam mobilnĂch zaĆĂzenĂ, pĆĂstupovĂœch cest a funkcĂ.
NÄr man undersÞger en casinos operatÞr og markedsramme, er det vigtigt at skelne mellem en licensoplysning og dokumentation for adgang i et bestemt land. For Hugo Casino er de tilgÊngelige oplysninger konkrete om Curacao, men de besvarer ikke alle spÞrgsmÄl om selskabsforhold eller lokal tilladelse.
For lÊsere, der undersÞger adgang fra Danmark, er Hugo casino ikke i sig selv dokumentation for, at tjenesten er godkendt eller tilgÊngelig pÄ det danske marked. Det beskrevne licensgrundlag bÞr derfor lÊses som en afgrÊnset oplysning om jurisdiktion, ikke som en bekrÊftelse af markedsstatus i et andet land.
Hugo Casino er knyttet til en eGaming License i Curacao. Oplysningen angiver Government of Curacao som den myndighed, der regulerer licensen. Det er den specifikke licensbetegnelse og jurisdiktion, der er dokumenteret; materialet angiver ikke et licensnummer eller en mere detaljeret beskrivelse af licensens tjenestetyper.
Der nÊvnes ogsÄ Curacao-lovgivning som det gÊldende lovgrundlag. Det giver en juridisk ramme for forhold, der hÞrer under den angivne jurisdiktion, men bÞr ikke forveksles med en oplysning om, at alle nationale regler, som kan vÊre relevante for en spiller, dermed er dÊkket eller tilsidesat. En jurisdiktionsangivelse fortÊller, hvilket lovsystem der refereres til i materialet, ikke automatisk hvordan reglerne anvendes i alle lande.
Det er nyttigt at holde tre forskellige spÞrgsmÄl adskilt, nÄr oplysningerne fortolkes:
Materialet angiver Curacao laws and legislations som gÊldende lovgivning. Det nÊvner desuden Courts of Curacao som vÊrneting for tvister og sÊrskilt som stedet, hvor betalingstvister skal behandles. At betalingskonflikter ogsÄ henvises til domstolene i Curacao, er en konkret del af den beskrevne juridiske ramme.
Disse oplysninger handler om lovvalg og forum for tvister; de beskriver ikke nÞdvendigvis alle praktiske trin i en klage, en afgÞrelse eller en eventuel hÄndhÊvelse. Der gives eksempelvis ikke en nÊrmere redegÞrelse for klageorganer, en tilsynsproces for individuelle sager eller hvilken procedure en kunde skal fÞlge fÞr en retssag. Det ville derfor vÊre for vidtgÄende at udlede sÄdanne ordninger alene af henvisningen til domstolene.
Den beskrevne licensinformation identificerer ikke den juridiske enhed, der stÄr bag driften, og den angiver heller ikke et licensnummer. Der er sÄledes forskel pÄ, at et brandnavn optrÊder som operatÞr, og at materialet identificerer et registreret selskab med navn og selskabsoplysninger. De to oplysninger kan ikke behandles som udskiftelige.
Oplysningerne fastslÄr heller ikke en sÊrskilt dansk tilladelse eller tilgÊngelighed i Danmark. En licens med tilknytning til Curacao kan ikke alene bruges til at konkludere, at et casino har tilladelse til at henvende sig til spillere pÄ ethvert andet nationalt marked. PÄ samme mÄde dokumenterer den ikke, at kontoadgang, indbetaling eller spil er tilladt for en bestemt person i et bestemt land.
Den forsigtige lÊsning er derfor afgrÊnset: Hugo Casino er beskrevet med en Curacao-baseret eGaming License, Curacao-lovgivning og domstolene i Curacao som forum for de nÊvnte tvister. Det er nyttig information om den angivne juridiske ramme, men ikke en fuldstÊndig beskrivelse af operatÞrens selskabsstruktur eller status pÄ det danske marked.
SpÞrger du, hvem der stÄr bag operatÞren, eller hvilken licens der er registreret? Det er to forskellige oplysninger: operatÞrnavnet identificerer den angivne aktÞr, mens licensoplysningerne beskriver den registrerede tilknytning til Curaçao.
Vores registrerede operatÞr er Hugo casino. Oplysningerne angiver ikke en sÊrskilt juridisk ejer eller en anden juridisk enhed, sÄ operatÞrnavnet bÞr ikke forveksles med dokumentation for et separat moderselskab.
Licensoplysningerne knytter casinoet til Curaçao og nÊvner en eGaming-licens reguleret af Curaçaos regering. De angiver ogsÄ Curaçaos love og lovgivning som gÊldende ret samt domstolene i Curaçao som vÊrneting for tvister. Det er de konkrete registrerede forhold; de giver ikke i sig selv grundlag for at drage bredere juridiske konklusioner.
De forskellige oplysninger kan lĂŠses hver for sig:
For en lÊser, der vil forstÄ markeds- og operatÞrkonteksten, er den centrale skelnen derfor enkel: Hugo Casino er det angivne operatÞrnavn, mens Curaçao fremgÄr i licens- og jurisdiktionsoplysningerne. Materialet angiver ikke en anden ejer, som kan fÞjes til den registrerede operatÞrprofil.
Wer unterwegs spielen oder Live-Angebote nutzen möchte, muss zuerst zwischen App und mobilem Browser unterscheiden. Dabei ist wichtig, nicht aus einer GerÀteangabe mehr herauszulesen, als sie tatsÀchlich sagt: Betriebssystem-KompatibilitÀt bedeutet nicht automatisch, dass jede Ansicht auf jedem GerÀt gleich funktioniert.
Die native App von Efbet ist ein installiertes Programm fĂŒr die unterstĂŒtzten Betriebssysteme Android und iOS. Der mobile Browser bietet dagegen einen Zugang ohne App-Installation; ob jede Funktion auf jedem GerĂ€t gleich dargestellt wird, lĂ€sst sich daraus nicht ableiten.
Die ausdrĂŒcklich ausgewiesene native App unterstĂŒtzt Android und iOS. Wer eines dieser Systeme nutzt und regelmĂ€Ăig mobil zugreifen will, kann daher zunĂ€chst die App als direkten Weg wĂ€hlen. Wer keine zusĂ€tzliche Anwendung installieren möchte, kann stattdessen den mobilen Browser ausprobieren, sofern die Website dort erreichbar ist.
FĂŒr die App nennt Efbet Cash Out, Partial Cash Out, Bet Builder und Live betting als Funktionen. AuĂerdem wird WebSocket-Echtzeitkommunikation aufgefĂŒhrt, also ein technischer Weg fĂŒr fortlaufende DatenĂŒbertragung. Diese Funktionsangaben beschreiben den mobilen Plattformumfang; sie versprechen nicht, dass jede einzelne Funktion in jeder Spielsituation oder auf jedem GerĂ€t verfĂŒgbar ist.
Die Tabelle stellt die beiden Zugangswege nach GerĂ€t und Installationsbedarf gegenĂŒber. So lĂ€sst sich der praktische Unterschied erkennen, ohne eine nicht belegte Gleichheit der mobilen Ansichten anzunehmen.
| Zugangsweg | GerÀtekontext | Installation |
|---|---|---|
| Native App | Android oder iOS | App auf dem GerÀt installieren |
| Mobiler Browser | Smartphone oder anderes GerÀt mit mobilem Browser | Keine separate App-Installation |
Am deutlichsten wirkt sich das Betriebssystem auf die Wahl der App aus: Die dokumentierte UnterstĂŒtzung umfasst Android und iOS. Andere Systeme oder GerĂ€te sollten Sie nicht als automatisch unterstĂŒtzt ansehen. Beim Browser entfĂ€llt die Installation, aber Darstellung und Bedienung hĂ€ngen allgemein vom verwendeten Browser und der BildschirmgröĂe ab. Eine besondere Optimierung oder eine vollstĂ€ndige Liste unterstĂŒtzter GerĂ€te ist nicht ausgewiesen.
Auch innerhalb der App ist der GerĂ€tebezug vor allem eine Frage der KompatibilitĂ€t und Bedienung, kein eigener Kontotyp. Cash Out und Partial Cash Out betreffen unterschiedliche Möglichkeiten, eine offene Wette vorzeitig abzurechnen; Bet Builder bĂŒndelt auswĂ€hlbare Wettbestandteile, und Live betting bezieht sich auf laufende Ereignisse. Die genannten Funktionen helfen bei der Entscheidung, ob die mobile App zu Ihrem geplanten Einsatz passt, Ă€ndern aber nicht grundsĂ€tzlich die Regeln fĂŒr den Zugang zum Konto.
Ein Wechsel vom Browser zur App ist kein Ersatz fĂŒr Kontoschutz. Nutzen Sie Ihre persönlichen Zugangsdaten nur selbst und melden Sie sich nach der Nutzung auf einem gemeinsam verwendeten GerĂ€t ab. Das passt zum Kontomodell von Efbet, das die persönliche Nutzung vorsieht und die Weitergabe von Zugangsdaten an Dritte ausschlieĂt.
FĂŒr DatenĂŒbertragungen wird SSL genannt. Das ist ein Schutz fĂŒr die Verbindung, aber kein Hinweis darauf, dass ein GerĂ€t automatisch als sicher erkannt oder freigegeben wird. Behandeln Sie daher die Wahl des Zugangswegs und die Sicherung des Kontos als zwei getrennte Entscheidungen: Das Betriebssystem hilft bei der Auswahl der App, wĂ€hrend der sorgfĂ€ltige Umgang mit Anmeldedaten unabhĂ€ngig davon wichtig bleibt.
FĂŒr einen gelegentlichen Zugriff kann der Browser der unkompliziertere Versuch sein; bei regelmĂ€Ăiger mobiler Nutzung ist die native App der klarer ausgewiesene Weg. Wenn die Darstellung im Browser oder die KompatibilitĂ€t des GerĂ€ts nicht passt, wechseln Sie zum unterstĂŒtzten App-System, statt daraus auf eine zusĂ€tzliche Sicherheitsfunktion zu schlieĂen.
A common mix-up is to treat identity verification as the same thing as protecting a sign-in. They serve different purposes: one checks who is using an account, while the other concerns access and personal data. For the 0xbet casino, our recorded measures span sign-in security, data protection and identity checks.
Two-factor authentication is available as an account-access measure. It is separate from identity verification, which has stated deposit and withdrawal triggers. Our privacy information also identifies the data controller and describes cookie use.
In short, two-factor authentication relates to account access, privacy measures address personal data and cookies, and identity checks apply at specified payment points. These are distinct safeguards rather than interchangeable requirements.
Per rispondere con precisione, occorre distinguere le slot dalle altre sezioni del catalogo. La categoria dedicata alle slot compare accanto a giochi da tavolo, contenuti dal vivo e altre forme di intrattenimento.
Questa distinzione aiuta a leggere la varietĂ senza confondere lâampiezza del catalogo con la selezione di slot vera e propria. Anche i titoli possono differire per ritmo e meccanica, pur appartenendo alla stessa categoria.
La scheda di Big Casino riporta 74 fornitori e registra le categorie CasinĂČ, Slot, CasinĂČ dal vivo, Sport virtuali, Video poker, Gratta e vinci, Jackpot, Blackjack e Roulette.
Per capire cosa puĂČ significare una selezione di slot, sono utili esempi concreti: alcuni giochi puntano su giri rapidi e funzioni bonus, altri costruiscono lâesperienza attorno a simboli e combinazioni particolari. Questi esempi illustrano meccaniche diverse, non una graduatoria nĂ© una promessa di vincita.
Il dato sulle categorie descrive lâorganizzazione generale della lobby; non specifica quanti titoli siano disponibili in ciascuna sezione. Di conseguenza, il numero di fornitori non va interpretato come conteggio delle slot: indica lâampiezza dei produttori presenti, mentre gli esempi mostrano come possano variare ritmo e meccaniche tra i singoli giochi.
Un errore frequente Ăš trattare il nome visibile di un casinĂČ come se identificasse automaticamente la societĂ proprietaria e chiarisse, da solo, dove il servizio Ăš accessibile. Sono questioni diverse: per Hugo casino, le informazioni disponibili associano un operatore e un contesto di licenza, ma non autorizzano a confonderli.
Unisciti a Hugo casino e scegli il tuo primo gioco.
La distinzione conta anche per lâaccount. Chi accede al servizio interagisce con una piattaforma che indica un operatore; il riferimento alla licenza, invece, riguarda il quadro giuridico e istituzionale riportato. Leggere insieme questi elementi aiuta a capire la struttura descritta, senza attribuirle significati ulteriori.
Il confronto fra la denominazione del gestore e i riferimenti istituzionali puĂČ essere affiancato alla presentazione italiana del sito, https://hugocasino.co.com/it/, senza scambiare il marchio mostrato agli utenti con una societĂ proprietaria identificata.
Lâoperatore indicato Ăš Hugo Casino. Separatamente, il contesto di licenza riporta una licenza eGaming associata a Curaçao, con il Governo di Curaçao indicato come autoritĂ di regolamentazione. Sono dati che descrivono aspetti collegati dellâattivitĂ , ma non sono intercambiabili: il primo nomina chi gestisce il servizio secondo le informazioni riportate, il secondo colloca la licenza in una giurisdizione.
Slot o tavoli live? Inizia su Hugo casino.
Questa separazione Ăš utile perchĂ© un marchio commerciale puĂČ essere quello con cui una persona riconosce un sito, mentre lâoperatore Ăš lâidentitĂ associata alla gestione. Il dato sullâoperatore non specifica, da solo, azionisti, societĂ madre o titolari del marchio. Non Ăš quindi corretto dedurre una struttura proprietaria precisa dal solo nome Hugo Casino.
La tabella distingue il soggetto operativo dai riferimenti giuridici e istituzionali associati alla licenza. Le voci mostrano quale funzione Ăš collegata a ciascun dato, senza trasformarle in una valutazione legale.
| Elemento | Dato associato |
|---|---|
| Operatore | Hugo Casino |
| Licenza | eGaming |
| Giurisdizione della licenza | Curaçao |
| Autorità di regolamentazione indicata | Governo di Curaçao |
| Legge applicabile indicata | Leggi e normative di Curaçao |
| Tribunali indicati per le controversie | Tribunali di Curaçao |
La presenza del nome dellâoperatore risponde a una domanda circoscritta: quale nome viene associato alla gestione del casinĂČ nelle informazioni disponibili? Non equivale a una visura societaria nĂ© chiarisce, da sola, quali persone o entitĂ possiedano il marchio. Per questo, la formulazione piĂč prudente Ăš riferirsi a Hugo Casino come operatore indicato, senza aggiungere una societĂ o un proprietario non specificati.
Anche la licenza va letta nel suo ambito. Giurisdizione, legge applicabile e tribunali sono riferimenti distinti: la prima identifica il contesto territoriale della licenza, mentre gli altri due riguardano rispettivamente il quadro normativo e il foro indicato per le controversie. La loro presenza non fornisce, da sola, una risposta a ogni domanda sulla titolaritĂ o sullâaccesso.
Per lâutente, lâidentitĂ dellâoperatore Ăš pertinente perchĂ© collega lâaccount al servizio fornito, mentre il contesto di licenza offre un riferimento diverso, di natura istituzionale. Non bisogna perĂČ dedurre dal solo riferimento a Curaçao che una persona possa o non possa registrarsi da un determinato paese: le informazioni riportate qui non stabiliscono la disponibilitĂ del servizio nei singoli mercati.
Allo stesso modo, la menzione di un operatore non basta a stabilire quali controlli siano applicati a ogni account, quali condizioni si applichino a un caso specifico o come venga risolta una controversia concreta. Sono questioni che richiedono informazioni pertinenti a quelle circostanze. La distinzione evita che un dato identificativo venga interpretato come una garanzia piĂč ampia.
Nel leggere il posizionamento di Hugo casino, dunque, conviene tenere separati tre livelli: il marchio riconoscibile, lâoperatore indicato e i riferimenti di licenza e giurisdizione. Insieme delineano un contesto operativo associato a Curaçao, ma non dimostrano una specifica struttura di proprietĂ nĂ© definiscono da soli lâaccessibilitĂ dellâaccount in ogni paese. Ă questa distinzione, piĂč che unâinterpretazione estesa dei dati, a chiarire il rapporto tra identitĂ e licenza.
Deze referentie beschrijft de beschikbare stortingsmethoden en de voorwaarden voor het opnemen van geld bij Slottio. Stortingen en opnames verschillen onder meer in betaalmethoden, verwerkingstijd en limieten.
De Nederlandse context van Slottio sluit aan bij deze feitelijke beschrijving van de betaalmogelijkheden.
De tabel vat de opgegeven verwerking, kosten en stortingsvoorwaarden samen. De verwerkingstijd geldt voor de meeste stortingen; een betaalprovider kan eigen kosten rekenen.
| Onderdeel | Voorwaarde |
|---|---|
| Verwerking | De meeste stortingen worden onmiddellijk of binnen enkele minuten verwerkt. |
| Kosten | Slottio rekent geen stortingskosten; de betaalprovider kan wel kosten rekenen. |
| Voorwaarde vóór opname | De eerste storting moet minstens eenmaal worden ingezet. |
| Rekeninghouder | Stortingen moeten van een persoonlijke rekening komen, niet van een zakelijke rekening. |
| Betaling door derden | Betalingen door derden zijn niet toegestaan. |
| Storting met cryptovaluta | Gebruik de actuele inloggegevens van de portemonnee. |
Voor stortingen zijn de volgende betaalmethoden vermeld.
De onderstaande limieten gelden voor opnames en zijn opgegeven per tijdvak. Er is geen maandlimiet vermeld.
| Tijdvak | Maximumbedrag | Valuta |
|---|---|---|
| 24 uur | 1.000 | EUR |
| 7 dagen | 2.000 | EUR |
Voor alle drie vermelde opnamekanalen geldt dezelfde minimumopname. De tabel koppelt elk kanaal aan dat bedrag.
| Opnamekanaal | Minimumopname |
|---|---|
| Bank | 100 EUR |
| Elektronische portemonnee | 100 EUR |
| Cryptovaluta | 100 EUR |
De volgende voorwaarden gaan over de verwerking en uitvoering van opnames. De verwerking duurt doorgaans maximaal drie bankwerkdagen, maar kan langer duren door de betaalroute, aanvullende accountcontroles of feestdagen.
| Onderdeel | Voorwaarde |
|---|---|
| Kosten | Slottio rekent geen opnamekosten; de betaalprovider kan wel kosten rekenen. |
| Betaalmethode | Een opname moet naar dezelfde betaalmethode gaan als de storting. |
| Aantal opnameverzoeken | Maximaal Ă©Ă©n opnameverzoek per 24 uur. |
| Openstaand verzoek | Per betaalmethode is tegelijk maximaal Ă©Ă©n opnameverzoek in behandeling. |
| Inzetvereisten | Opnameverzoeken worden pas verwerkt nadat aan alle inzetvereisten is voldaan. |
| Uitbetalingsrekening | Opnames naar rekeningen van derden worden niet uitgevoerd. |
| Benodigde inzet | Een opname kan worden geweigerd als het totale ingezette bedrag lager is dan de laatste storting. |
| Verwerking | Elektronische portemonnees zijn doorgaans sneller dan bankoverschrijvingen. |
De verificatievoorwaarden zijn van belang bij stortingen en opnames. Een opnameverzoek leidt altijd tot een verificatievereiste; doorgaans is de controle binnen 48 uur afgerond.
| Aanleiding | Vereiste |
|---|---|
| Stortingen vanaf 2.000 EUR | Verificatie is vereist. |
| Elk opnameverzoek | Verificatie is vereist. |
| Verwerking van de verificatie | Doorgaans binnen 48 uur afgerond. |
Voor de verificatie kunnen de volgende documenten worden gevraagd.
NÀr en spelobby rymmer mÄnga titlar kan det vara svÄrt att veta var man ska börja. Det blir enklare att navigera om du först skiljer mellan spelens format och dÀrefter jÀmför de funktioner som faktiskt pÄverkar spelrundan.
Slottios spelutbud omfattar slots, live-spel och sport, och katalogen anges ha 23 spelleverantörer. Det gör det klokt att hÄlla fokus pÄ slotdelen nÀr mÄlet Àr att hitta en viss typ av hjulspel, snarare Àn att blÀddra igenom hela spelutbudet.
Utbud och tillgÀnglighet kan variera, sÄ kontrollera den aktuella spelvyn hos Slottio innan du vÀljer en titel. Börja med de kategorier eller sökverktyg som faktiskt visas i lobbyn, i stÀllet för att förutsÀtta att en viss filterfunktion finns.
En titelbild eller ett tema sÀger inte alltid sÀrskilt mycket om hur en slot fungerar. Titta i stÀllet efter sÄdant som antal hjul, hur vinster bildas och om bonusfunktioner pÄverkar spelet. Tabellen visar vanliga format och kÀnnetecken att leta efter; den beskriver speltyper generellt, inte en garanti för att varje typ finns i Slottios aktuella katalog.
| Format | KĂ€nnetecken |
|---|---|
| Klassisk slot | Ofta fÄ hjul och enkla symbolkombinationer |
| Videoslot | Kan ha flera vinstlinjer och bonusfunktioner |
| Slot med vinstvÀgar | Vinster kan bildas genom intilliggande matchande symboler |
| Megaways-slot | Antalet symbolpositioner kan variera mellan hjulen |
Se formatnamnen som ledtrÄdar, inte som ett mÄtt pÄ hur lÀtt ett spel Àr att förstÄ eller vinna i. TvÄ videoslots kan exempelvis skilja sig mycket Ät i bonusrundor och vinstsÀtt, medan ett enkelt hjulupplÀgg fortfarande kan ha en hög eller lÄg spelvarians. LÀs dÀrför spelets informationsruta nÀr du vill förstÄ regler, symboler och eventuella specialfunktioner.
En kort urvalsprocess minskar risken att fastna vid enbart grafik eller vÀlkÀnda namn:
Leverantörsnamnet kan hjÀlpa dig att orientera dig, men det ersÀtter inte spelreglerna. Slottios leverantörsutbud omfattar bland annat Pragmatic, Play'n GO och Hacksaw. En leverantör kan ge en fingervisning om vilka spelserier eller visuella uttryck du stöter pÄ, men det Àr spelets egen informationsruta som visar hur just den titeln fungerar.
Om sökresultatet blandar slots med andra delar av lobbyn, gÄ tillbaka till slotkategorin och börja om med ett smalare urval. PÄ sÄ sÀtt blir den praktiska skillnaden tydlig: först hitta rÀtt speltyp, sedan kontrollera spelets regler och sist jÀmföra funktioner mellan nÀrliggande titlar.